Development and Validation of Interpretable Machine Learning Models for Clinically Significant Prostate Cancer Diagnosis in Patients With Lesions of PI‐RADS v2.1 Score ≥3
Background For patients with PI‐RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required. Purpose To develop and validate machine learning (ML) models based...
Saved in:
Published in | Journal of magnetic resonance imaging Vol. 60; no. 5; pp. 2130 - 2141 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.11.2024
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
For patients with PI‐RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required.
Purpose
To develop and validate machine learning (ML) models based on clinical and imaging parameters for csPCa detection in patients with PI‐RADS v2.1 ≥ 3.
Study Type
Retrospective.
Subjects
One thousand eighty‐three patients with PI‐RADS v2.1 ≥ 3, randomly split into training (70%, N = 759) and validation (30%, N = 324) datasets, and 147 patients enrolled prospectively for testing.
Field Strength/Sequence
3.0 T scanners/T2‐weighted fast spin echo sequence and DWI with diffusion‐weighted single‐shot gradient echo planar imaging sequence.
Assessment
The factors evaluated for csPCa detection were age, prostate specific antigen, prostate volume, and the diameter and location of the index lesion, PI‐RADSv2.1. Five ML models for csPCa detection were developed: logistic regression (LR), extreme gradient boosting, random forest (RF), decision tree, and support vector machines. The csPCa was defined as Gleason grade ≥2.
Statistical Tests
Univariable and multivariable LR analyses to identify parameters associated with csPCa. Area under the receiver operating characteristic curve (AUC), Brier score, and DeLong test were used to assess and compare the csPCa diagnostic performance with the LR model. The significance level was defined as 0.05.
Results
The RF model exhibited the highest AUC (0.880–0.904) and lowest Brier score (0.125–0.133) among the ML models in the validation and testing cohorts, however, there was no difference when compared to the LR model (P = 0.453 and 0.548). The sensitivity and negative predictive values in the validation and testing cohorts were 93.8%–97.6% and 82.7%–95.1%, respectively, at a threshold of 0.450 (99% sensitivity of the RF model).
Data Conclusion
The RF model might help for assessing the risk of csPCa and preventing overdiagnosis and unnecessary biopsy for men with PI‐RADSv2.1 ≥ 3.
Evidence Level
3
Technical Efficacy
Stage 2 |
---|---|
AbstractList | For patients with PI-RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required.BACKGROUNDFor patients with PI-RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required.To develop and validate machine learning (ML) models based on clinical and imaging parameters for csPCa detection in patients with PI-RADS v2.1 ≥ 3.PURPOSETo develop and validate machine learning (ML) models based on clinical and imaging parameters for csPCa detection in patients with PI-RADS v2.1 ≥ 3.Retrospective.STUDY TYPERetrospective.One thousand eighty-three patients with PI-RADS v2.1 ≥ 3, randomly split into training (70%, N = 759) and validation (30%, N = 324) datasets, and 147 patients enrolled prospectively for testing.SUBJECTSOne thousand eighty-three patients with PI-RADS v2.1 ≥ 3, randomly split into training (70%, N = 759) and validation (30%, N = 324) datasets, and 147 patients enrolled prospectively for testing.3.0 T scanners/T2-weighted fast spin echo sequence and DWI with diffusion-weighted single-shot gradient echo planar imaging sequence.FIELD STRENGTH/SEQUENCE3.0 T scanners/T2-weighted fast spin echo sequence and DWI with diffusion-weighted single-shot gradient echo planar imaging sequence.The factors evaluated for csPCa detection were age, prostate specific antigen, prostate volume, and the diameter and location of the index lesion, PI-RADSv2.1. Five ML models for csPCa detection were developed: logistic regression (LR), extreme gradient boosting, random forest (RF), decision tree, and support vector machines. The csPCa was defined as Gleason grade ≥2.ASSESSMENTThe factors evaluated for csPCa detection were age, prostate specific antigen, prostate volume, and the diameter and location of the index lesion, PI-RADSv2.1. Five ML models for csPCa detection were developed: logistic regression (LR), extreme gradient boosting, random forest (RF), decision tree, and support vector machines. The csPCa was defined as Gleason grade ≥2.Univariable and multivariable LR analyses to identify parameters associated with csPCa. Area under the receiver operating characteristic curve (AUC), Brier score, and DeLong test were used to assess and compare the csPCa diagnostic performance with the LR model. The significance level was defined as 0.05.STATISTICAL TESTSUnivariable and multivariable LR analyses to identify parameters associated with csPCa. Area under the receiver operating characteristic curve (AUC), Brier score, and DeLong test were used to assess and compare the csPCa diagnostic performance with the LR model. The significance level was defined as 0.05.The RF model exhibited the highest AUC (0.880-0.904) and lowest Brier score (0.125-0.133) among the ML models in the validation and testing cohorts, however, there was no difference when compared to the LR model (P = 0.453 and 0.548). The sensitivity and negative predictive values in the validation and testing cohorts were 93.8%-97.6% and 82.7%-95.1%, respectively, at a threshold of 0.450 (99% sensitivity of the RF model).RESULTSThe RF model exhibited the highest AUC (0.880-0.904) and lowest Brier score (0.125-0.133) among the ML models in the validation and testing cohorts, however, there was no difference when compared to the LR model (P = 0.453 and 0.548). The sensitivity and negative predictive values in the validation and testing cohorts were 93.8%-97.6% and 82.7%-95.1%, respectively, at a threshold of 0.450 (99% sensitivity of the RF model).The RF model might help for assessing the risk of csPCa and preventing overdiagnosis and unnecessary biopsy for men with PI-RADSv2.1 ≥ 3.DATA CONCLUSIONThe RF model might help for assessing the risk of csPCa and preventing overdiagnosis and unnecessary biopsy for men with PI-RADSv2.1 ≥ 3.3 TECHNICAL EFFICACY: Stage 2.EVIDENCE LEVEL3 TECHNICAL EFFICACY: Stage 2. BackgroundFor patients with PI‐RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required.PurposeTo develop and validate machine learning (ML) models based on clinical and imaging parameters for csPCa detection in patients with PI‐RADS v2.1 ≥ 3.Study TypeRetrospective.SubjectsOne thousand eighty‐three patients with PI‐RADS v2.1 ≥ 3, randomly split into training (70%, N = 759) and validation (30%, N = 324) datasets, and 147 patients enrolled prospectively for testing.Field Strength/Sequence3.0 T scanners/T2‐weighted fast spin echo sequence and DWI with diffusion‐weighted single‐shot gradient echo planar imaging sequence.AssessmentThe factors evaluated for csPCa detection were age, prostate specific antigen, prostate volume, and the diameter and location of the index lesion, PI‐RADSv2.1. Five ML models for csPCa detection were developed: logistic regression (LR), extreme gradient boosting, random forest (RF), decision tree, and support vector machines. The csPCa was defined as Gleason grade ≥2.Statistical TestsUnivariable and multivariable LR analyses to identify parameters associated with csPCa. Area under the receiver operating characteristic curve (AUC), Brier score, and DeLong test were used to assess and compare the csPCa diagnostic performance with the LR model. The significance level was defined as 0.05.ResultsThe RF model exhibited the highest AUC (0.880–0.904) and lowest Brier score (0.125–0.133) among the ML models in the validation and testing cohorts, however, there was no difference when compared to the LR model (P = 0.453 and 0.548). The sensitivity and negative predictive values in the validation and testing cohorts were 93.8%–97.6% and 82.7%–95.1%, respectively, at a threshold of 0.450 (99% sensitivity of the RF model).Data ConclusionThe RF model might help for assessing the risk of csPCa and preventing overdiagnosis and unnecessary biopsy for men with PI‐RADSv2.1 ≥ 3.Evidence Level3Technical EfficacyStage 2 Background For patients with PI‐RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required. Purpose To develop and validate machine learning (ML) models based on clinical and imaging parameters for csPCa detection in patients with PI‐RADS v2.1 ≥ 3. Study Type Retrospective. Subjects One thousand eighty‐three patients with PI‐RADS v2.1 ≥ 3, randomly split into training (70%, N = 759) and validation (30%, N = 324) datasets, and 147 patients enrolled prospectively for testing. Field Strength/Sequence 3.0 T scanners/T2‐weighted fast spin echo sequence and DWI with diffusion‐weighted single‐shot gradient echo planar imaging sequence. Assessment The factors evaluated for csPCa detection were age, prostate specific antigen, prostate volume, and the diameter and location of the index lesion, PI‐RADSv2.1. Five ML models for csPCa detection were developed: logistic regression (LR), extreme gradient boosting, random forest (RF), decision tree, and support vector machines. The csPCa was defined as Gleason grade ≥2. Statistical Tests Univariable and multivariable LR analyses to identify parameters associated with csPCa. Area under the receiver operating characteristic curve (AUC), Brier score, and DeLong test were used to assess and compare the csPCa diagnostic performance with the LR model. The significance level was defined as 0.05. Results The RF model exhibited the highest AUC (0.880–0.904) and lowest Brier score (0.125–0.133) among the ML models in the validation and testing cohorts, however, there was no difference when compared to the LR model (P = 0.453 and 0.548). The sensitivity and negative predictive values in the validation and testing cohorts were 93.8%–97.6% and 82.7%–95.1%, respectively, at a threshold of 0.450 (99% sensitivity of the RF model). Data Conclusion The RF model might help for assessing the risk of csPCa and preventing overdiagnosis and unnecessary biopsy for men with PI‐RADSv2.1 ≥ 3. Evidence Level 3 Technical Efficacy Stage 2 For patients with PI-RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required. To develop and validate machine learning (ML) models based on clinical and imaging parameters for csPCa detection in patients with PI-RADS v2.1 ≥ 3. Retrospective. One thousand eighty-three patients with PI-RADS v2.1 ≥ 3, randomly split into training (70%, N = 759) and validation (30%, N = 324) datasets, and 147 patients enrolled prospectively for testing. 3.0 T scanners/T2-weighted fast spin echo sequence and DWI with diffusion-weighted single-shot gradient echo planar imaging sequence. The factors evaluated for csPCa detection were age, prostate specific antigen, prostate volume, and the diameter and location of the index lesion, PI-RADSv2.1. Five ML models for csPCa detection were developed: logistic regression (LR), extreme gradient boosting, random forest (RF), decision tree, and support vector machines. The csPCa was defined as Gleason grade ≥2. Univariable and multivariable LR analyses to identify parameters associated with csPCa. Area under the receiver operating characteristic curve (AUC), Brier score, and DeLong test were used to assess and compare the csPCa diagnostic performance with the LR model. The significance level was defined as 0.05. The RF model exhibited the highest AUC (0.880-0.904) and lowest Brier score (0.125-0.133) among the ML models in the validation and testing cohorts, however, there was no difference when compared to the LR model (P = 0.453 and 0.548). The sensitivity and negative predictive values in the validation and testing cohorts were 93.8%-97.6% and 82.7%-95.1%, respectively, at a threshold of 0.450 (99% sensitivity of the RF model). The RF model might help for assessing the risk of csPCa and preventing overdiagnosis and unnecessary biopsy for men with PI-RADSv2.1 ≥ 3. 3 TECHNICAL EFFICACY: Stage 2. |
Author | Wu, Shiliang Wang, Xiaoying Liu, Yi Wang, Kexin Yao, Kaifeng Ruan, Mingjian Fan, Yu |
Author_xml | – sequence: 1 givenname: Mingjian surname: Ruan fullname: Ruan, Mingjian organization: National Urological Cancer Center of China – sequence: 2 givenname: Yi surname: Liu fullname: Liu, Yi organization: National Urological Cancer Center of China – sequence: 3 givenname: Kaifeng surname: Yao fullname: Yao, Kaifeng organization: National Urological Cancer Center of China – sequence: 4 givenname: Kexin surname: Wang fullname: Wang, Kexin organization: School of Basic Medical Sciences, Capital Medical University – sequence: 5 givenname: Yu surname: Fan fullname: Fan, Yu email: dantefanbmu@pku.edu.cn organization: Drug Clinical Trial Institution, Peking University First Hospital – sequence: 6 givenname: Shiliang orcidid: 0000-0002-0712-9929 surname: Wu fullname: Wu, Shiliang email: wushiliangjsh@263.net organization: National Urological Cancer Center of China – sequence: 7 givenname: Xiaoying orcidid: 0000-0001-6406-0895 surname: Wang fullname: Wang, Xiaoying email: cjr.wangxiaoying@vip.163.com organization: Peking University First Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38363125$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1uEzEUhUeoiP7AhgdAltggpAn-zcwsq4SfoERETQVLyzNznTry2Kk9Kcqu2-54CfY8U54Ep2k3FWJ1faXvnGPdc5odOe8gy14TPCAY0w-rLpgBrWghnmUnRFCaU1EOj9IbC5aTEhfH2WmMK4xxVXHxIjtmJRsyQsVJ9mcMN2D9ugPXI-Va9F1Z06reeIe8RhPXQ1gH6FVtAc1Uc2UcoCmo4IxboplvwUakfUAja5xplLVbtDBLZ3RakuU8-NirHtBIuQYCGhu1dD6aiIxD85STciP6Yfqr5BpTatzHzie7218X5-MFuqEDghaND7C7vdvd_WYvs-da2QivHuZZdvnp4-XoSz799nkyOp_mDROFyHU7pIUWVU2roqCtxoQzxivcMuC1BqpVKzAua1wpXQk-bEvFVMkVKeumpJidZe8OtuvgrzcQe9mZ2IC1yoHfRJnOXVJecU4T-vYJuvKb4NLnJCNEYM4w44l680Bt6g5auQ6mU2ErH6tIAD4ATTpZDKBlY_r7IvqgjJUEy33bct-2vG87Sd4_kTy6_hMmB_insbD9Dym_zi4mB81feFq9vw |
CitedBy_id | crossref_primary_10_1002_jmri_29277 |
Cites_doi | 10.1038/s41391-021-00417-1 10.1111/bju.15277 10.1016/j.eururo.2019.08.005 10.2307/2531595 10.1002/jmri.27692 10.1056/NEJMoa1801993 10.1001/jamanetworkopen.2023.30233 10.1016/j.eururo.2019.02.033 10.1111/bju.13465 10.1093/jnci/djj131 10.1016/j.eururo.2015.08.038 10.1007/s00330-020-07027-w 10.1038/s41585-019-0193-3 10.1890/07-0539.1 10.2196/22394 10.1007/s11548-021-02507-w 10.1016/j.eururo.2017.01.033 10.1007/s00345-020-03177-0 10.1097/PAS.0000000000000530 10.1038/s41585-019-0212-4 10.1038/aja.2012.28 10.1002/pros.21475 |
ContentType | Journal Article |
Copyright | 2024 International Society for Magnetic Resonance in Medicine. 2024 International Society for Magnetic Resonance in Medicine |
Copyright_xml | – notice: 2024 International Society for Magnetic Resonance in Medicine. – notice: 2024 International Society for Magnetic Resonance in Medicine |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7TK 8FD FR3 K9. P64 7X8 |
DOI | 10.1002/jmri.29275 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Neurosciences Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Engineering Research Database Biotechnology Research Abstracts Technology Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1522-2586 |
EndPage | 2141 |
ExternalDocumentID | 38363125 10_1002_jmri_29275 JMRI29275 |
Genre | researchArticle Validation Study Journal Article |
GrantInformation_xml | – fundername: National High Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital) funderid: 2022CR16; 2023IR27 – fundername: National High Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital) grantid: 2022CR16 – fundername: National High Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital) grantid: 2023IR27 |
GroupedDBID | --- -DZ .3N .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHMBA AIACR AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HDBZQ HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RX1 RYL SAMSI SUPJJ SV3 TEORI TWZ UB1 V2E V8K V9Y W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WVDHM WXI WXSBR XG1 XV2 ZXP ZZTAW ~IA ~WT AAHHS AAYXX ACCFJ AEEZP AEQDE AIWBW AJBDE CITATION CGR CUY CVF ECM EIF NPM 7QO 7TK 8FD FR3 K9. P64 7X8 |
ID | FETCH-LOGICAL-c3575-fd627f59b29772df01433490d3e4bfe2fad5008b09af9546d8a3a84a18bc8203 |
IEDL.DBID | DR2 |
ISSN | 1053-1807 1522-2586 |
IngestDate | Fri Jul 11 07:32:19 EDT 2025 Fri Jul 25 12:05:41 EDT 2025 Thu Apr 03 07:07:58 EDT 2025 Thu Apr 24 23:06:41 EDT 2025 Tue Jul 01 03:57:02 EDT 2025 Sun Jul 06 04:45:31 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | prostate biopsy prostate cancer random forest machine learning |
Language | English |
License | 2024 International Society for Magnetic Resonance in Medicine. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3575-fd627f59b29772df01433490d3e4bfe2fad5008b09af9546d8a3a84a18bc8203 |
Notes | Mingjian Ruan and Yi Liu contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0001-6406-0895 0000-0002-0712-9929 |
PMID | 38363125 |
PQID | 3115043034 |
PQPubID | 1006400 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_2928249442 proquest_journals_3115043034 pubmed_primary_38363125 crossref_citationtrail_10_1002_jmri_29275 crossref_primary_10_1002_jmri_29275 wiley_primary_10_1002_jmri_29275_JMRI29275 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November 2024 |
PublicationDateYYYYMMDD | 2024-11-01 |
PublicationDate_xml | – month: 11 year: 2024 text: November 2024 |
PublicationDecade | 2020 |
PublicationPlace | Hoboken, USA |
PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Nashville |
PublicationSubtitle | JMRI |
PublicationTitle | Journal of magnetic resonance imaging |
PublicationTitleAlternate | J Magn Reson Imaging |
PublicationYear | 2024 |
Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
References | 2021; 25 2017; 119 2021; 23 2019; 53 2023; 6 2006; 98 2019; 76 2021; 127 2020; 17 2019; 16 2020; 77 2012; 14 2012; 72 2017; 72 2021; 54 2023 2020; 30 2021 2021; 39 2018; 378 1988; 44 2016; 40 2017 2007; 88 2016; 69 e_1_2_7_6_1 e_1_2_7_5_1 Oerther B (e_1_2_7_7_1) 2021; 25 Peng T (e_1_2_7_23_1) 2021 e_1_2_7_4_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_26_1 Robinson D (e_1_2_7_3_1) 2023; 6 e_1_2_7_25_1 e_1_2_7_24_1 e_1_2_7_22_1 e_1_2_7_21_1 Mottet N (e_1_2_7_17_1) 2019; 53 e_1_2_7_20_1 |
References_xml | – volume: 378 start-page: 1767 year: 2018 end-page: 1777 article-title: MRI‐targeted or standard biopsy for prostate‐cancer diagnosis publication-title: N Engl J Med – volume: 14 start-page: 738 year: 2012 end-page: 744 article-title: External validation of the prostate cancer prevention trial and the European randomized study of screening for prostate cancer risk calculators in a Chinese cohort publication-title: Asian J Androl – start-page: 2235 year: 2021 end-page: 2249 article-title: Can machine learning‐based analysis of multiparameter MRI and clinical parameters improve the performance of clinically significant prostate cancer diagnosis? publication-title: Int J Comput Assist Radiol Surg – volume: 72 start-page: 721 year: 2012 end-page: 729 article-title: Can the prostate risk calculator based on western population be applied to Asian population? publication-title: Prostate – volume: 40 start-page: 244 year: 2016 end-page: 252 article-title: The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma definition of grading patterns and proposal for a new grading system publication-title: Am J Surg Pathol – volume: 17 start-page: 41 year: 2020 end-page: 61 article-title: Multiparametric MRI for prostate cancer diagnosis: Current status and future directions publication-title: Nat Rev Urol – volume: 30 start-page: 6877 year: 2020 end-page: 6887 article-title: Machine learning for the identification of clinically significant prostate cancer on MRI: A meta‐analysis publication-title: Eur Radiol – volume: 16 start-page: 391 year: 2019 end-page: 403 article-title: A new era: Artificial intelligence and machine learning in prostate cancer publication-title: Nat Rev Urol – volume: 119 start-page: 225 year: 2017 end-page: 233 article-title: Combination of prostate imaging reporting and data system (PI‐RADS) score and prostate‐specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients publication-title: BJU Int – volume: 25 start-page: 256 issue: 2 year: 2021 end-page: 263 article-title: Cancer detection rates of the PI‐RADSv2.1 assessment categories: systematic review and meta‐analysis on lesion level and patient level publication-title: Prostate Cancer Prostatic Dis – volume: 127 start-page: 175 year: 2021 end-page: 178 article-title: Risk‐adapted biopsy decision based on prostate magnetic resonance imaging and prostate‐specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation publication-title: BJU Int – volume: 98 start-page: 529 year: 2006 end-page: 534 article-title: Assessing prostate cancer risk: Results from the prostate cancer prevention trial publication-title: J Natl Cancer Inst – year: 2023 – volume: 69 start-page: 41 year: 2016 end-page: 49 article-title: Synopsis of the PI‐RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use publication-title: Eur Urol – volume: 44 start-page: 837 year: 1988 end-page: 845 article-title: Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach publication-title: Biometrics – volume: 77 start-page: 38 year: 2020 end-page: 52 article-title: Recent global patterns in prostate cancer incidence and mortality rates publication-title: Eur Urol – volume: 39 start-page: 73 year: 2021 end-page: 80 article-title: Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) risk calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculator in Chinese and Europ publication-title: World J Urol – volume: 76 start-page: 340 year: 2019 end-page: 351 article-title: Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2 publication-title: Eur Urol – year: 2017 – volume: 53 start-page: 1 year: 2019 end-page: 161 article-title: EAU‐EANM‐ESTRO‐ESUR‐SIOG guidelines on prostate cancer 2019 publication-title: Eur Assoc Urol Guide – volume: 23 year: 2021 article-title: Radiomic and genomic machine learning method performance for prostate cancer diagnosis: Systematic literature review publication-title: J Med Internet Res – volume: 54 start-page: 1466 year: 2021 end-page: 1473 article-title: Magnetic resonance imaging radiomics‐based machine learning prediction of clinically significant prostate cancer in equivocal PI‐RADS 3 lesions publication-title: J Magn Reson Imaging – volume: 88 start-page: 2783 issue: 11 year: 2007 end-page: 2792 article-title: Random Forests for Classification in Ecology publication-title: Ecology – volume: 6 year: 2023 article-title: Frequency of biopsy and tumor grade before vs after introduction of prostate magnetic resonance imaging publication-title: JAMA Netw Open – volume: 72 start-page: 45 year: 2017 end-page: 51 article-title: Improving the Rotterdam European randomized study of screening for prostate cancer risk calculator for initial prostate biopsy by incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth publication-title: Eur Urol – volume: 25 start-page: 256 issue: 2 year: 2021 ident: e_1_2_7_7_1 article-title: Cancer detection rates of the PI‐RADSv2.1 assessment categories: systematic review and meta‐analysis on lesion level and patient level publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/s41391-021-00417-1 – ident: e_1_2_7_6_1 doi: 10.1111/bju.15277 – ident: e_1_2_7_16_1 doi: 10.1016/j.eururo.2019.08.005 – ident: e_1_2_7_15_1 doi: 10.2307/2531595 – volume: 53 start-page: 1 year: 2019 ident: e_1_2_7_17_1 article-title: EAU‐EANM‐ESTRO‐ESUR‐SIOG guidelines on prostate cancer 2019 publication-title: Eur Assoc Urol Guide – ident: e_1_2_7_24_1 doi: 10.1002/jmri.27692 – ident: e_1_2_7_14_1 – ident: e_1_2_7_13_1 doi: 10.1056/NEJMoa1801993 – volume: 6 year: 2023 ident: e_1_2_7_3_1 article-title: Frequency of biopsy and tumor grade before vs after introduction of prostate magnetic resonance imaging publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2023.30233 – ident: e_1_2_7_4_1 doi: 10.1016/j.eururo.2019.02.033 – ident: e_1_2_7_26_1 doi: 10.1111/bju.13465 – ident: e_1_2_7_19_1 doi: 10.1093/jnci/djj131 – ident: e_1_2_7_5_1 – ident: e_1_2_7_11_1 doi: 10.1016/j.eururo.2015.08.038 – ident: e_1_2_7_9_1 doi: 10.1007/s00330-020-07027-w – ident: e_1_2_7_10_1 doi: 10.1038/s41585-019-0193-3 – ident: e_1_2_7_25_1 doi: 10.1890/07-0539.1 – ident: e_1_2_7_8_1 doi: 10.2196/22394 – start-page: 2235 year: 2021 ident: e_1_2_7_23_1 article-title: Can machine learning‐based analysis of multiparameter MRI and clinical parameters improve the performance of clinically significant prostate cancer diagnosis? publication-title: Int J Comput Assist Radiol Surg doi: 10.1007/s11548-021-02507-w – ident: e_1_2_7_18_1 doi: 10.1016/j.eururo.2017.01.033 – ident: e_1_2_7_20_1 doi: 10.1007/s00345-020-03177-0 – ident: e_1_2_7_12_1 doi: 10.1097/PAS.0000000000000530 – ident: e_1_2_7_2_1 doi: 10.1038/s41585-019-0212-4 – ident: e_1_2_7_21_1 doi: 10.1038/aja.2012.28 – ident: e_1_2_7_22_1 doi: 10.1002/pros.21475 |
SSID | ssj0009945 |
Score | 2.4518511 |
Snippet | Background
For patients with PI‐RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in... For patients with PI-RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically... BackgroundFor patients with PI‐RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2130 |
SubjectTerms | Aged Biopsy Clinical significance Decision trees Diffusion Magnetic Resonance Imaging - methods Diffusion rate Echo-Planar Imaging - methods Field strength Humans Image Interpretation, Computer-Assisted - methods Learning algorithms Lesions Machine Learning Magnetic Resonance Imaging - methods Male Medical imaging Middle Aged Parameter identification Prostate - diagnostic imaging Prostate - pathology prostate biopsy Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - pathology random forest Regression analysis Reproducibility of Results Retrospective Studies Risk Assessment ROC Curve Sensitivity analysis Statistical analysis Statistical tests Support vector machines |
Title | Development and Validation of Interpretable Machine Learning Models for Clinically Significant Prostate Cancer Diagnosis in Patients With Lesions of PI‐RADS v2.1 Score ≥3 |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmri.29275 https://www.ncbi.nlm.nih.gov/pubmed/38363125 https://www.proquest.com/docview/3115043034 https://www.proquest.com/docview/2928249442 |
Volume | 60 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9QwEMetqgfEhfcjtKBBcAEp26ztJLbEpWqp2kqLVrsFekGRndhtIM2izS4SnHrtjS_Bnc-0nwQ_slkKCAlukWLHiWYm-cUe_wehp0Uec8ZEGoooESEVRRxKLnmoFU54X7NcOwW-watk_zU9PI6P19CL5V4Yrw_RTbjZyHDvaxvgQjZbK9HQ92fTsoc5Tu0Oc5usZYlotNKO4txVKDb8QMI-i9JOmxRvrbpe_hr9hpiXidV9cvauo3fLm_WZJh9685ns5V9-0XH836e5ga61LArb3nluojVV30JXBu1q-230_aeMIhB1AW8MtPsaTDDRsMpXlJWCgcvKVNAKtp6ArbJWNWCgGFrx0ar6DOPypLbZScagMLQ7Tgzrwo51vSns-rS_soGyhqEXfG3gbTk7NVe1s3qNHXZ4sDj_OtreHcMn3OvD2OpwLs4vFhffyB10tPfyaGc_bCs8hDkxnBjqIsGpjrnEBkNxoa3YIKE8Koii0riLNr5jIEVGXGge06RggghGRZ_J3KALuYvW60mt7iPAURyL3NCYTjBNmXE3gVVCdIpVIUiaBujZ0tBZ3qqf2yIcVeZ1m3FmLZA5CwToSdf2o9f8-GOrzaW_ZG3cN5nVLrIqaoQG6HF32kSsXYYRtZrMG9ubmZ9eSnGA7nk_64YhjCTEMGeAnjtv-cv42eFgdOCOHvxL4w10FRsu89spN9H6bDpXDw1XzeQjFz8_AO6RIjM |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Pb9MwFMctGBJw4TcsMMAILiClS20nsY_TxtSOdaraArtFTmKPjJCipkWC06678U9w52_qX4KfnaUMEBLcIsWOFb334m_s589D6FmehYJzGfsyiKTPZB76qUiFrxWJRFfzTFsC3-Ag6r1me4fhYZObA2dhHB-iXXCDyLDfawhwWJDeXFFDjz_Mig4RJA4voktQ0tv-UY1W9CghbI1ioyCo3-VB3NJJyeaq7_n56DeReV6z2kln97qrrFpbViHkmrzvLOZpJ_vyC8nxv9_nBrrWyFG85fznJrqgqlvo8qDZcL-Nvv-UVIRlleM3Rre7Mkx4qvEqZTEtFR7YxEyFG2brEYZCa2WNjS7GDX-0LD_jcXFUQYKSsSkewqETI3fxNnjfDO-4zL-ixkWFh475WuO3xfydeSos7NUw7LC_PPk62toZ40-k08VjQHEuT06Xp9_oHTTZfTnZ7vlNkQc_o0Yq-jqPSKxDkRKjREmugTdImQhyqlhqPEYb9zE6JQ2E1CJkUc4llZzJLk8zo17oXbRWTSu1jjAJwlBmRpDpiLCYG4-TREVUx0Tlksaxh56fWTrJGgA61OEoE4duJglYILEW8NDTtu1Hh_34Y6uNM4dJmtCvE8AXAUiNMg89aW-boIWdGFmp6aKG3tz89zJGPHTPOVo7DOU0okZ2euiFdZe_jJ_sDUZ9e3X_Xxo_Rld6k8F-st8_ePUAXSVGprnTlRtobT5bqIdGZs3TRzaYfgDrViZO |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Nb9MwGMcfjSFNXHh_CQx4EFxASpfaTmJLXKaVah10qtoBu0yR8-IRKOnUtEhw2nU3vgR3PlM_CXacpgwQEtwixYkT-f8k_ziPfw_AkzTxBecydKUXSJfJ1HdjEQtXZSQQbcUTVRH4-vvB7mu2d-gfrsHz5VoYy4doJtxMZFTPaxPgJ6naWkFD33-c5i0iSOhfgIss8LjRdGe4gkcJUZUo1gaCum3uhQ2clGytjj3_OvrNY563rNU7p3sFjpZXa1NNPrTms7iVfPkF5Pi_t3MVLtdmFLeteq7BWlZch41-_bv9Bnz_KaUIZZHiG-3abREmnChcJSzG4wz7VVpmhjWx9RhNmbVxidoVY00fHY8_4yg_Lkx6kh5RHJglJ9rs4o7R3hQ7Nu8vLzEvcGCJryW-zWfv9FnNtF5puh30Fqdfh9udEX4irTaODIhzcXq2OPtGb8JB98XBzq5bl3hwE6qNoqvSgITKFzHRPpSkytAGKRNeSjMWa70oLR7tUmJPSCV8FqRcUsmZbPM40d6F3oL1YlJkdwCJ5_sy0XZMBYSFXOtNkiygKiRZKmkYOvB0OdBRUuPPTRWOcWTBzSQyIxBVI-DA46btiYV-_LHV5lIvUR34ZWTgRQajRpkDj5rdOmTNfxhZZJN5aY7m-quXMeLAbauzphvKaUC16XTgWaWWv_Qf7fWHvWrr7r80fggbg043etXbf3kPLhHt0ezSyk1Yn03n2X3tsWbxgyqUfgCFZiUG |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+and+Validation+of+Interpretable+Machine+Learning+Models+for+Clinically+Significant+Prostate+Cancer+Diagnosis+in+Patients+With+Lesions+of+PI-RADS+v2.1+Score%E2%80%89%E2%89%A53&rft.jtitle=Journal+of+magnetic+resonance+imaging&rft.au=Ruan%2C+Mingjian&rft.au=Liu%2C+Yi&rft.au=Yao%2C+Kaifeng&rft.au=Wang%2C+Kexin&rft.date=2024-11-01&rft.issn=1522-2586&rft.eissn=1522-2586&rft.volume=60&rft.issue=5&rft.spage=2130&rft_id=info:doi/10.1002%2Fjmri.29275&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1053-1807&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1053-1807&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1053-1807&client=summon |